SCHEMBL6318012

SCHEMBL6318012

NC(=O)c1c(-c2ccsc2)noc1NC(=O)CCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.51
FLT3 P36888 1/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
HTT P42858 2/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 3/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316643 0.86 MAPK14 (0.67) MAPK14FLT3RAB9ANPC1HTT
SCHEMBL27591902 0.85 MAPK14 (0.52) MAPK14FLT3RAB9ANPC1HTT
SCHEMBL6317993 0.84 ADORA1 (0.51) MAPTPOLBALDH1A1GAAMEN1
SCHEMBL6318380 0.83 ALDH1A1 (0.55) MAPK14FLT3RAB9ANPC1HTT
SCHEMBL6315238 0.83 ADORA1 (0.44) MAPK14RAB9AMAPTPOLBALDH1A1
SCHEMBL6316187 0.81 KIT (0.46) MAPK14FLT3RAB9ANPC1MAPT
SCHEMBL27610090 0.81 MAPK14 (0.54) MAPK14RAB9ANPC1HTTMAPT
SCHEMBL6317985 0.80 MAPK14 (0.51) MAPK14POLBMEN1KMT2ALMNA
SCHEMBL6318208 0.80 RAB9A (0.51) MAPK14FLT3RAB9ANPC1HTT
SCHEMBL6319055 0.80 MEN1 (0.39) HTTMAPTHPGDALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPK14 111/4885FLT3 721/4885RAB9A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.